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Tetrabenazine (TBZ), a high affinity and specific inhibitor of the vesicular monoamine transporter, 
has been labeled with carbon-l 1 as a potential probe for in viva positron emission tomographic imaging 
of monoaminergic neuronal losses in neurodegenerative diseases. [“CITBZ was synthesized by 
O-[“Clmethylation of the 9-0-desmethylTBZ using [“C]methyl iodide in the presence of tetrabutyl- 
ammonium hydroxide. The radiochemical yields were 35-55% (decay corrected) and the synthesis time 
32-37 min from EOB. [“CITBZ was obtained with specific activities of 2000-2500 Ci/mmol (EOS) and 
radiochemical and chemical purities were ~95%. [“ClTetrabenazine is a promising new radioligand for 
the in viuo study of monoaminergic neurons using PET. 
Introduction 
Numerous potential neuronal imaging agents based 
on the neuronal monoamine reuptake system have 
been developed, and several of these [[“Clcocaine, 
Fowler et al. (1989); [“Clnomifensine, Salmon et al. 
(1990); [‘*F]GBR 12909, Koeppe et al. (1990)] are 
currently being evaluated in human subjects using 
positron emission tomography (PET). The imaging of 
vesicular neurotransmitter uptake sites would form 
an alternative method for quantification of neuronal 
densities. Tetrabenazine (TBZ) is a high affinity 
[IC& = 3 nM, Scherman et al. (1988a)] specific inhibi- 
tor of the monoamine transporter of the presynaptic 
vesicular membrane, and shows more CNS specifi- 
city, a shorter duration of monoamine depletion and 
a greater selectivity for depletion of brain catechol- 
amines (dopamine and norepinephrine > serotonin) 
as compared to reserpine (Pettibone et al., 1984; 
Scherman, 1986; Henry and Scherman, 1989). 
[‘HlDihydrotetrabenazine ([3H]TBZOH) has been re- 
cently used as a radioligand for in vitro homogenate 
and autoradiographic studies of the monoamine 
vesicular transporter, and shows high specific 
binding in the striatum of rodents (Scherman et al., 
1988b). In 6-hydroxydopamine-lesioned rats, loss of 
[3H]TBZOH sites correlated well with loss of tyrosine 
hydroxylase activity (Masuo et al., 1990), and post- 
mortem studies of brains of patients with Parkinson’s 
disease revealed lower binding of [‘HITBZOH in the 
*Author for correspondence. 
caudate nucleus and the putamen (- 73 and - 87%) 
as compared to controls (Scherman et al., 1989). 
Tetrabenazine is thus a potential candidate for 
development as a new PET radiotracer to measure 
losses of dopaminergic neurons in neurodegenerative 
disorders, such as Parkinson’s disease. The high 
binding affinity, moderate lipophilicity [log P = 2.68, 
Scherman et al. (1988a)] and low toxicity (Pletscher 
et al., 1962) of this clinically used drug is particularly 
encouraging. Development of related labeled benzo- 
quinolizine derivatives for single photon emission 
computed tomography (SPECT) imaging is being 
pursued by others (Canney et al., 1993). We report 
here the synthesis of tetrabenazine in carbon-l 1 form 
as a potential radioligand for studying monoaminer- 
gic terminal losses in neurological diseases using PET. 
Materials 
Experimental 
Tetrabenazine was purchased from Fluka and 
boron triiodide was obtained from Johnson Matthey 
Chemicals Ltd; all other chemicals and solvents were 
obtained from Aldrich Chem. Co., and were used 
without further purification. Sep-Pak C,, cartridges 
were purchased from Waters Associates. Thin-layer 
chromatography was performed on 0.25 mm What- 
man glass-backed silica gel plates (60A K6F), with 
CHCl,/methanol (24/l) as eluting solvent mixture. 
Semi-preparative HPLC was done using a Partisil 10 
silica gel column (10 mm, 25 x 0.94 cm) eluted with 
CH,Cl,/hexane/isopropanol 85/14/l at a flow rate of 
6 mL/min. The HPLC system was fitted with in-line 
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detectors for U.V. (286 nm) and radioactivity (y-detec- 
tor). ‘H-NMR chemical shifts are reported relative to 
tetramethylsilane as an internal reference. Low-resol- 
ution mass spectrum (MS) and high-resolution mass 
spectrum (HRMS) were determined in the chemical 
ionization mode (ammonia); data are expressed in 
m/z (intensity relative to base peak = 100). Elemental 
analysis was performed by Spang Microanalytical 
Laboratory, Eagle Arbor, MI. 
2-0x0-3-isobutyl-9-hydroxy- IO-methoxy- 1,3,4,6,7- 
hexahydro-llbH-benzo [alquinolizine (destnethyl- 
TBZ, 2) 
Tetrabenazine (1, 3.77 g, 11.9 mmol) was dissolved 
in dichloromethane (IO mL), a N, atmosphere intro- 
duced and the mixture cooled to -76C in a dry 
ice/isopropanol bath. A solution of BI, (95%, 4.9 g, 
1 equiv.) in CH,Cl, (23.8 mL) was added dropwise 
over 5-IOmin. After stirring for 5 min at room 
temperature, the reaction was quenched with a satu- 
rated aqueous solution (100 mL) of NaHCO, con- 
taining sodium bisulfite. The aqueous layer was 
extracted with CH,Cl, (3 x 150 mL) and the extracts 
dried over Na,SO,, filtered and evaporated to dry- 
ness The residue was purified (3 x) by column 
chromatography (280 g silica gel, gradient 
CHCl,/methanol 99/l-CHCl,/methanol 99/5) to give 
2 as an oil. DesmethylTBZ (2) was further purified by 
semi-preparative HPLC (CH,Cl,/hexane/isopropanol 
50/49/l, 4 mL/min, t, = 11.6 min) and dried over 
KOH under vacuum to provide an oil (72 mg, 2 %): 
TLC, R, = 0.43; ‘H-NMR (CDCl, 360 MHz) 6 0.95 
(d, 3H, J = 6.60, CH,), 0.98 (d, 3H, J = 6.60, CH,), 
3.89 (s, 3H, OCH,), 6.64 (s, lH, 11-H) 7.20 (s, lH, 
8-H); MS (CL, NH,) m/z 304 ([M + l]+, 100%); 
anal. (HRMS) calcd for [C,,H,,N03--H] + : 304.1913. 
Found: 304.1900; anal. calcd for C,BH,,NO,: C, 71.26; 
H, 8.31; N, 4.62. Found: C, 71.31; H, 8.34; N, 4.55. 
Production of [“C]methyl iodide 
[“C]Carbon dioxide was produced via the 
“N(p,a)“C reaction using nitrogen in an all- 
aluminum target. [“CICO, was then converted 
to [“C]methyl iodide by LiAIH, reduction followed 
by treatment with HI (Crouzel et al., 1987; Jewett, 
1987). 
Synthesis of [“CITBZ ([“C]I) 
[“ClTetrabenazine was prepared by O- 
[“Clmethylation of desmethylTBZ with [“Clmethyl 
iodide (Fig. l), utilizing the apparatus used for 
the synthesis of [“C]( + )2a-tropanylbenzilate (Mul- 
holland et al., 1992). [“C]Methyl iodide was trapped 
in a reaction vessel containing desmethylTBZ 
(free base, 1.0 mg) and tetrabutylammonium hy- 
droxide (TBAOH, MeOH solution, 1.8 mL, 0.55 
equiv.) in DMF (200 mL) at - 30 to -40°C. After 
heating at 20°C for 5 min, water (0.5 mL) was 
added to the mixture and the solution was transferred 
onto a short reversed phase column filled with 
C,, Sep-Pak packing that was pre-washed with 
MeOH (50 mL) and water (100 mL). The extraction 
column was rinsed with water (1 .O mL) and blown 
dry with Nz (80 psi) for 2 min. The HPLC solvent 
was then passed through this short column onto 
a silica gel semi-preparative HPLC column. The 
radioactive peak corresponding to [“CITBZ 
(tR = 9.0 min; phenol 2, t, = >20 min) was col- 
lected into a sterile vial placed in a warm water 
bath (30-4O”C) and the solvent removed by N, flow. 
The residue was formulated in a sterile solution of 
isotonic phosphate buffer (pH 6.0) and then filtered 
through a 0.2 pm alumina filter (Anotop) into a 




Fig. I. Synthesis of [“C]TBZ ([“Cll). 
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Analyses of [ “Cl1 
HPLC. An aliquot was removed from the final 
formulation of [“C]TBZ and assayed for chemical 
and radiochemical purity, and specific activity 
determination by analytical HPLC, using an Ultre- 
mex column (5 mm, 25 x 0.46cm) eluted with 
CH$N/KH,PO, (10 mM) 65/35, 1.5 mL/min 
(ta = 6.1 min) in series with U.V. (286 nm) and y- 
radioactivity detectors. Typical chemical and radio- 
chemical purities were >95%, and specific activities 
at end of synthesis varied between 2000-2500 
Ci/mmol. Identity of the radioactive product as 
[“C]TBZ was determined by co-injection with auth- 
entic TBZ. 
TLC. A sample of the radioactive fraction from 
semi-preparative HPLC after evaporation of the sol- 
vent was co-spotted on TLC with authentic TBZ. The 
radioactive product ([“CITBZ) showed the same R, 
(0.62) as compared to authentic TBZ, and chemical 
(254 nm u.v.) and radiochemical purities were 
>99%. 
showed two methoxy groups at 3.83 and 3.86ppm, 
whereas that of desmethylTBZ exhibited only one 
methoxy group at 3.89 ppm. The presence of only one 
methoxy signal for 2 indicates that the demethylation 
with BI, was selective, however, it does not tell 
which methoxy group had been cleaved. The assign- 
ment of the hydroxyl and the methoxyl group was 
determined by comparing the chemical shifts of the 
aromatic protons of TBZ and desmethylTBZ with 
the published NMR spectra of structurally similar 
demethylated derivatives of protoberberines. The two 
aromatic protons of desmethylTBZ isolated in this 
work show singlets at 6 720 and 6 6.64, consistent with 
the chemical shifts at 67.43 and 66.53 observed for 
dehydrodiscretine [3; Chen et al. (198O)j but different 
from those of apocavidine [4: 66.78 and 66.58; Yu 
et al. (1970)], which represents an analogue with the 
other methoxy group cleaved (Fig. 2). Tetrabenazine, 
with both methoxy groups intact, shows singlets at 
66.55 and 66.62. Based on these comparisons, we 
have assigned the hydroxyl group to C-9 and the 
methoxyl group to C-10 in the desmethylTBZ iso- 
lated in this work. 
Results and Discussion 
Synthesis of [“Cltetrabenazine 
Preparation cf desmethylTBZ 
The demethylation of TBZ was carried out in 
low yields (2-10%) using BI, in dichloromethane 
(Lansinger and Ronald, 1979). The product was 
repeatedly purified by column chromatography and 
HPLC until completely free of contamination with 
unreacted TBZ or catechol; this extensive purification 
accounted for part of the overall low yield of this 
synthesis. Demethylation of TBZ with BBr, gave a 
mixture of both 9- and IO-desmethylTBZ in poor 
yields, while almost no demethylation occurred with 
iodotrimethylsilane (McOmie et al., 1968; Vickery 
et al., 1979). Although the overall yield was low, 
demethylation of TBZ was faster and more con- 
venient than the optional total synthesis of 
desmethylTBZ. 
Assignment of the structure of desmethylTBZ (2) 
The structure of desmethylTBZ (2) was determined 
using a combination of ‘H-NMR, MS, HRMS and 
elemental analysis. The ‘H-NMR spectrum of TBZ 
[“CITBZ was successfully synthesized in high 
radiochemical yields (35-55%, decay corrected based 
on [“C]CO,) and high specific activities (2000- 
2500Ci/mmol, end of synthesis) within 32-37min 
from end of beam in high chemical and radiochemical 
purities (> 95%). Higher radiochemical yields could 
be obtained in the production of [“CITBZ by adding 
more TBAOH or by increasing the reaction tempera- 
ture, but more side products were also formed. 
However, using 0.55 equiv. of base (TBAOH) in 
DMF at room temperature gave only a few percent 
of side products and acceptable yields of [“CITBZ. 
The identity of [“CITBZ was confirmed by compari- 
son of HPLC retention times and TLC R, values, 
which were identical to those of authentic TBZ. 
Biodistribution studies in mice with [“CITBZ showed 
good brain penetration, with high specific uptake in 
the striatum (rich in vesicular transporters for dopa- 
mine) and lesser uptake in other brain regions, and 
specific binding could be blocked by coinjection of 
unlabeled TBZ or pretreatment with reserpine 
7.20 7.43 6.56 
If tf ‘: 
Fig. 2. Structures and ‘H-NMR assignments for aromatic protons of desmethylTBZ (2), dehydrodiscretine 
(3) and apocavidene (4). 
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(DaSilva and Kilbourn, 1992). [“CITBZ is currently 
being evaluated in human subjects using PET. 
In summary, [“CITBZ has been synthesized by 
O-[“Clmethylation of desmethylTBZ with [“Cl- 
methyl iodide as a potential probe for in vivo imaging 
of monoaminergic terminal losses in neurological 
diseases using PET. Future evaluation of this radio- 
tracer will include in vivo displacement studies in 
mice, determination of possible metabolites in blood 
and tissues, and kinetic studies of the regional brain 
distribution in primates and humans using PET. 
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